User login
Key clinical point: This meta-analysis demonstrated the superiority of peppermint oil over placebo for improvements in the signs and symptoms of irritable bowel syndrome (IBS); however, adverse events were more frequent with peppermint oil use.
Major finding: Peppermint oil was superior to placebo for global IBS symptoms (relative risk [RR] for persisting global IBS symptoms 0.65; 95% CI 0.43-0.98) and abdominal pain (RR for no improvement in abdominal pain 0.76; 95% CI 0.62-0.93) after therapy. The rate of any adverse events (RR 1.57; 95% CI 1.04-2.37), particularly gastroesophageal reflux symptoms, was higher among patients receiving peppermint oil.
Study details: The data come from a meta-analysis of 10 randomized controlled trials including 1030 patients with IBS, of which 525 were assigned to receive peppermint oil.
Disclosures: This study received no external funding. No conflicts of interest were declared.
Source: Ingrosso MR et al. Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022 (Aug 9). Doi: 10.1111/apt.17179
Key clinical point: This meta-analysis demonstrated the superiority of peppermint oil over placebo for improvements in the signs and symptoms of irritable bowel syndrome (IBS); however, adverse events were more frequent with peppermint oil use.
Major finding: Peppermint oil was superior to placebo for global IBS symptoms (relative risk [RR] for persisting global IBS symptoms 0.65; 95% CI 0.43-0.98) and abdominal pain (RR for no improvement in abdominal pain 0.76; 95% CI 0.62-0.93) after therapy. The rate of any adverse events (RR 1.57; 95% CI 1.04-2.37), particularly gastroesophageal reflux symptoms, was higher among patients receiving peppermint oil.
Study details: The data come from a meta-analysis of 10 randomized controlled trials including 1030 patients with IBS, of which 525 were assigned to receive peppermint oil.
Disclosures: This study received no external funding. No conflicts of interest were declared.
Source: Ingrosso MR et al. Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022 (Aug 9). Doi: 10.1111/apt.17179
Key clinical point: This meta-analysis demonstrated the superiority of peppermint oil over placebo for improvements in the signs and symptoms of irritable bowel syndrome (IBS); however, adverse events were more frequent with peppermint oil use.
Major finding: Peppermint oil was superior to placebo for global IBS symptoms (relative risk [RR] for persisting global IBS symptoms 0.65; 95% CI 0.43-0.98) and abdominal pain (RR for no improvement in abdominal pain 0.76; 95% CI 0.62-0.93) after therapy. The rate of any adverse events (RR 1.57; 95% CI 1.04-2.37), particularly gastroesophageal reflux symptoms, was higher among patients receiving peppermint oil.
Study details: The data come from a meta-analysis of 10 randomized controlled trials including 1030 patients with IBS, of which 525 were assigned to receive peppermint oil.
Disclosures: This study received no external funding. No conflicts of interest were declared.
Source: Ingrosso MR et al. Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022 (Aug 9). Doi: 10.1111/apt.17179